SCHEMBL3887663

SCHEMBL3887663

COc1ccc(NC(=O)C(=O)c2c(-c3ccccc3)cc3c(OC)cccn23)cn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.47
PDE4B Q07343 1/20 0.47
PDE4C Q08493 1/20 0.47
PDE4D Q08499 1/20 0.47
NPC1 O15118 6/20 0.46
LMNA P02545 6/20 0.46
PKM P14618 1/20 0.46
KMT2A Q03164 5/20 0.44
ALDH1A1 P00352 4/20 0.44
MEN1 O00255 4/20 0.44
POLB P06746 2/20 0.44
RAB9A P51151 6/20 0.44
HTT P42858 3/20 0.44
KDM4E B2RXH2 2/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
CCKBR P32239 1/20 0.43
USP2 O75604 1/20 0.42
TSHR P16473 1/20 0.42
CASP3 P42574 1/20 0.42
SENP8 Q96LD8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1645267 0.91 PDE4A (0.47) PDE4APDE4BPDE4CPDE4DNPC1
SCHEMBL4553955 0.90 PDE4A (0.49) PDE4APDE4BPDE4CPDE4DNPC1
SCHEMBL1645543 0.86 THRB (0.56) PDE4APDE4BPDE4CPDE4DNPC1
SCHEMBL3884080 0.86 LMNA (0.44) NPC1LMNAKMT2AALDH1A1MEN1
SCHEMBL3898847 0.86 POLB (0.46) NPC1LMNAKMT2AALDH1A1MEN1
SCHEMBL1644501 0.82 LMNA (0.45) PDE4APDE4BPDE4CPDE4DNPC1
SCHEMBL4617518 0.80 LMNA (0.37) PDE4APDE4BPDE4CPDE4DLMNA
SCHEMBL1644316 0.80 THRB (0.48) PDE4APDE4BPDE4CPDE4DNPC1
SCHEMBL1644535 0.80 THRB (0.48) PDE4APDE4BPDE4CPDE4DNPC1
SCHEMBL1646043 0.80 LMNA (0.45) PDE4APDE4BPDE4CPDE4DNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8486962-B2 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus F2G LTD. (GB) 2013-07-16 US disclosed
EP-1888063-B1 ANTIFUNGAL AGENTS F2G LTD (GB) 2009-01-14 EP disclosed
US-20080161302-A1 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus F2G LTD. (GB) 2008-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161302-A1 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus NAT1, CYP1A2, CYP51A1 PDE4A 844/4885PDE4B 818/4885PDE4C 1524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.